Since we're all waiting for the interim readout, i wanted to share a few links to give everyone an indication of what the possible outcomes are. Pluristem have an interim readout coming for their pivotal Phase III Critical Limb Ischemia (CLI) Study which reads:
https://www.sec.gov/Archives/edgar/data/1158780/000121390020018046/ea124396ex99-1_pluristem.htmThe interim process and possible outcomes:
An analysis of the interim data will have three possible outcomes: a) an earlier than planned end-of-study may be achieved if the top line interim data analysis achieves overwhelming efficacy (p ≤0.01), b) the study may be declared futile if there is no probability of successfully achieving the primary endpoint on the full data set after enrolling all patients, or c) the study is in line with the protocol assumptions and considered to be in a promising zone for success. If the third possible outcome results, Pluristem will continue to enroll patients, and will analyze the data again on the full data set.
And if we achieve overwhelming efficacy we can expect the following:
The DSMB recommended the study be stopped "due to overwhelming evidence of efficacy seen in the predefined interim analysis,"
The DSMB's conclusion is "[whatever DSMB's analysis uncovers]"
The interim analysis results will likely be sent to the FDA which may then consider fast-tracked submission for review and accelerated approval for the product in the U.S.
https://www.streetwisereports.com/article/2018/07/31/interim-readout-for-pharma-trial-delivers-home-run.html
- Forums
- ASX - By Stock
- MSB
- Overwhelming efficacy - the stats required
Overwhelming efficacy - the stats required, page-190
-
- There are more pages in this discussion • 387 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
-0.020(2.08%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
95.5¢ | 97.0¢ | 93.5¢ | $1.424M | 1.507M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 29390 | 93.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 14089 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 24054 | 0.935 |
8 | 131583 | 0.930 |
4 | 65851 | 0.925 |
7 | 113334 | 0.920 |
9 | 97006 | 0.915 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 1100 | 1 |
0.950 | 19026 | 2 |
0.955 | 27000 | 2 |
0.960 | 32869 | 2 |
0.965 | 35384 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online